Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #80 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| NGL Fine-Chem Limited (this stock) | 1,846 | 36.6 | 14.6% | 101.7% | 0.06% | 77 | 37 | 68 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 139 | 24 | 18 | ₹ |
| March 31, 2026 | 149 | 18 | 13 | ₹ |
| Dec. 31, 2025 | 128 | 21 | 16 | ₹ |
| Sept. 30, 2025 | 120 | 13 | 10 | ₹ |
| June 30, 2025 | 104 | 12 | 9 | ₹ |
| March 31, 2025 | 95 | 1 | 1 | ₹ |
| Dec. 31, 2024 | 89 | 1 | 1 | ₹ |
| Sept. 30, 2024 | 93 | 13 | 10 | ₹ |
| June 30, 2024 | 91 | 12 | 9 | ₹ |
| March 31, 2024 | 100 | 16 | 12 | ₹ |
| Dec. 31, 2023 | 88 | 14 | 10 | ₹ |
| Sept. 30, 2023 | 80 | 14 | 10 | ₹ |
| June 30, 2023 | 71 | 10 | 9 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 501 | 63 | 48 |
| March 31, 2025 | 368 | 28 | 21 |
| March 31, 2024 | 339 | 54 | 41 |
| March 31, 2023 | 278 | 27 | 20 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 43 | -71 | 30 | 90 | -47 |
| March 31, 2025 | 36 | -35 | -1 | 131 | -95 |
| March 31, 2024 | 20 | -27 | -1 | 29 | -8 |
| March 31, 2023 | 35 | -27 | -1 | 31 | 4 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 545 | 329 | 326 | 52 | 56 | 276 | 150 | 3 | 164 | 70 |
| March 31, 2025 | 433 | 282 | 279 | 48 | 25 | 235 | 119 | 1 | 142 | 51 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
